Literature DB >> 18223695

The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.

B Sadeghi1, M Jansson, Z Hassan, M Mints, H Hägglund, M Abedi-Valugerdi, M Hassan.   

Abstract

Conditioning regimens are an important issue determining the outcome of hematopoietic stem cell transplantation (HSCT). Less toxicity, early engraftment and no relapse are the aims of efficient conditioning. Our objective was to investigate the long-term effects of BU-CY and their administration order on the toxicity and chimerism in a mouse model of HSCT. Female BALB/c mice were treated with either BU (15 mg/kg/day x 4)-CY (100 mg/kg/day x 2) or CY-BU. Treated mice were transplanted with Sca-1+ cells from male BALB/c mice. Until 90 days after HSCT, the animals were monitored for body weight and analyzed for cellular phenotype of the thymus, spleen and BM, total chimerism, the spleen chimerism of DCs and T regulatory (Treg) cells, and hepatotoxicity. BU-CY and CY-BU treatments exerted comparable myeloablative and immunosuppressive effects. The long-term engraftment of donor cells in the BM and thymus regeneration showed the same features in both groups. However, the two regimens differed; in general, hepatotoxicity and chimerism of DC and Treg cells. In the long term, BU-CY, but not CY-BU caused a marked decrease in body weight and a significant increase in the activities of the liver enzymes, particularly aspartate amino transferase (AST). We conclude that the alteration of the administration order of BU-CY to CY-BU not only gives the same level of engraftment but also reduces the toxicity of the conditioning regimen that might be valuable specially in young patients who are undergoing HSCT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223695     DOI: 10.1038/sj.bmt.1705996

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration.

Authors:  M E Dourthe; N Ternès; D Gajda; A Paci; C Dufour; E Benhamou; D Valteau-Couanet
Journal:  Bone Marrow Transplant       Date:  2016-04-25       Impact factor: 5.483

2.  A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies.

Authors:  Xiaojin Cai; Jialing Wei; Yi He; Dongling Yang; Erlie Jiang; Yong Huang; Mingzhe Han; Sizhou Feng
Journal:  Int J Clin Pharm       Date:  2014-11-29

3.  Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.

Authors:  Andrew R Rezvani; Jeannine S McCune; Barry E Storer; Ami Batchelder; Aiko Kida; H Joachim Deeg; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-10       Impact factor: 5.742

4.  Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice.

Authors:  Mohammad A Rafi; Han Zhi Rao; Paola Luzi; David A Wenger
Journal:  Mol Ther       Date:  2015-09-02       Impact factor: 11.454

5.  Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway.

Authors:  Ibrahim El-Serafi; Ylva Terelius; Manuchehr Abedi-Valugerdi; Seán Naughton; Maryam Saghafian; Ali Moshfegh; Jonas Mattsson; Zuzana Potácová; Moustapha Hassan
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

6.  The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation.

Authors:  Ibrahim El-Serafi; Mats Remberger; Ahmed El-Serafi; Fadwa Benkessou; Wenyi Zheng; Eva Martell; Per Ljungman; Jonas Mattsson; Moustapha Hassan
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

7.  Priming mobilization of hair follicle stem cells triggers permanent loss of regeneration after alkylating chemotherapy.

Authors:  Jin Yong Kim; Jungyoon Ohn; Ji-Seon Yoon; Bo Mi Kang; Minji Park; Sookyung Kim; Woochan Lee; Sungjoo Hwang; Jong-Il Kim; Kyu Han Kim; Ohsang Kwon
Journal:  Nat Commun       Date:  2019-08-27       Impact factor: 14.919

8.  Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Ibrahim El-Serafi; Mats Remberger; Olle Ringdèn; Johan Törlén; Mikael Sundin; Andreas Björklund; Jacek Winiarski; Jonas Mattsson
Journal:  Clin Transl Sci       Date:  2019-11-06       Impact factor: 4.689

9.  Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.

Authors:  Claire Seydoux; Michael Medinger; Sabine Gerull; Joerg Halter; Dominik Heim; Yves Chalandon; Stavroula Masouridi Levrat; Urs Schanz; Gayathri Nair; Marc Ansari; Patrick Simon; Jakob R Passweg; Nathan Cantoni
Journal:  Ann Hematol       Date:  2020-10-23       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.